L2IP - Instituto de Pesquisas Clínicas - FC072920211954380192
Welcome,         Profile    Billing    Logout  
 32 Trials 
95 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Tae Won
NEMO, NCT03128021: Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response

Completed
4
57
US
Escitalopram Pill, Lexapro, Placebo, Levomilnacipran Pill, Fetzima
Howard Aizenstein, Weill Cornell Institute of Geriatric Psychiatry, National Institute of Mental Health (NIMH)
Major Depressive Disorder
06/23
08/23
OPTIMIZE-APT, NCT05418556: Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent

Recruiting
4
3944
RoW
aspirin, clopidogrel, prasugrel, ticagrelor
Asan Medical Center
Coronary Artery Disease
08/27
12/28
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Recruiting
3
510
Europe, Canada, Japan, US, RoW
LY3650150, Placebo, Standard therapy for INCS
Eli Lilly and Company
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
10/26
02/27
NCT06545526: Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis

Recruiting
3
28
RoW
celecoxib monotherapy, celecoxib and metformin combination
Yonsei University
Familial Adenomatous Polyposis
06/26
06/26
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
NCT04296851: Niclosamide for Familial Adenomatous Polyposis

Recruiting
2
72
RoW
Niclosamide, placebo
Yonsei University
Familial Adenomatous Polyposis
12/22
02/23
NCT03435107: Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Completed
2
33
RoW
Durvalumab
Asan Medical Center
Metastatic Colorectal Cancer
04/23
04/23
DYNAMIC, NCT04954339: DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab

Active, not recruiting
2
40
RoW
Aatezolizumab plus Bevacizumab, Ticentriq plus Avastin
Tae Won Kim
Hepatocellular Carcinoma
06/26
12/26
SPECTRUM, NCT05253118: Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)

Active, not recruiting
2
28
RoW
Tislelizumab, BGB-A317, Pemetrexed
Seoul National University Hospital, Gyeongsang National University Hospital, Kyunghee University Medical Center, Inje University Haeundae Paik Hospital, Chungnam National University Hospital
DLBCL
12/25
02/26
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
140
Europe, Canada, Japan, US, RoW
Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
12/27
09/28
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
FORTE, NCT05503797 / 2022-000627-20: A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Recruiting
2
250
Europe, Canada, US, RoW
Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R)
Fore Biotherapeutics, Fore Biotherapeutics
Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors, Melanoma BRAF V600E/K Mutated, Thyroid Cancer
06/26
12/26
ACE, NCT05741060: Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers

Active, not recruiting
2
372
US
S-equol, Equelle, Placebo
Akira Sekikawa, National Institute on Aging (NIA)
Arterial Stiffness, White Matter Lesions, Cognitive Decline
10/26
01/27
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
NCT04696848: The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors

Terminated
1/2
25
RoW
CKD-516 plus Durvalumab, CKD-516 plus MEDI4736
Tae Won Kim
Colorectal Cancer, Solid Tumor
03/23
03/23
KEYNOTE-877, NCT03674567: Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

Completed
1/2
323
US, RoW
FLX475, pembrolizumab (KEYTRUDA®)
RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC
Advanced Cancer
12/24
12/24
NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Recruiting
1/2
110
US, RoW
EU101
Eutilex
Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer
09/25
12/25
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
NCT05394831: A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

Recruiting
1/2
150
US, RoW
JIN-A02
J Ints Bio
EGFR Mutant Advanced Non-small Cell Lung Cancer
09/26
09/26
DF1001-001, NCT04143711 / 2019-004706-10: Study of DF1001 in Patients with Advanced Solid Tumors

Recruiting
1/2
378
Europe, US, RoW
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics, Dragonfly Therapeutics, Inc.
Solid Tumor, Adult
10/26
12/26
IDE397-001, NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting
1
180
Europe, US, RoW
IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan
IDEAYA Biosciences
Solid Tumor
12/26
03/27
NCT03284502: HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
148
RoW
HM95573, cobimetinib, HM95573, cetuximab
Hanmi Pharmaceutical Company Limited
Locally Advanced Solid Tumor, Metastatic Solid Tumor
09/24
12/24
NCT05159440: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Active, not recruiting
1
70
US, RoW
TORL-2-307-MAB
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
12/24
12/25
NCT05156866: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Recruiting
1
70
US, RoW
TORL-2-307-ADC
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
02/26
02/27
ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting
1
198
Europe, US, RoW
ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1
Enliven Therapeutics
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
07/26
07/26
RELIF-C, NCT02865369: Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment

Not yet recruiting
N/A
103
RoW
Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks
Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb
Chronic Hepatitis C
12/18
12/22
NCT04656405: Efficacy of Online Real-time CPR Training

Recruiting
N/A
180
RoW
Online real-time quality measurement and feedback video-based CPR training, Online real-time feedback video-based CPR training without quality measurement, Conventional CPR training
Seoul National University Hospital
Cardiopulmonary Resuscitation, Education
12/21
03/22
NCT04239794: The Influence of Type of Anesthesia on Postoperative Pain

Active, not recruiting
N/A
468
RoW
Propofol, Propofol 2%, Sevoflurane, Sevoflurane inhalant product
Seoul National University Hospital
Colo-rectal Cancer, Anesthesia
12/23
01/24
NCT04203849: Prospective Cohort Study of Breast Cancer Patients Treated With Radiotherapy

Enrolling by invitation
N/A
5000
RoW
National Cancer Center, Korea
Breast Cancer
06/22
06/34
NCT05100485: Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108)

Completed
N/A
1000
RoW
Esophagogasrtoduodendoscopy, Hepatic venous pressure gradient
Hepatopancreatobiliary Surgery Institute of Gansu Province, Tianjin Second People's Hospital, The Third People's Hospital of Taiyuan, Ehime University Graduate School of Medicine, Korea University Ansan Hospital, Hyogo Medical University, Zagazing University Faculty of Medicine, Institute of Liver and Biliary Sciences (ILBS), Changi General Hospital, Ruijin Hospital
Compensated Advanced Chronic Liver Disease
01/23
01/23
NCT05559502: High Flow Nasal Oxygenation vs Endotracheal Intubation on Recovery Profiles in Laryngeal Microsurgery

Recruiting
N/A
52
RoW
HFNO group, Optiflow, ET group, Portex, Smiths Medical International Ltd., South East England, United Kingdom
Ajou University School of Medicine
Cough
06/24
06/24
NCT03969823: Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

Active, not recruiting
N/A
148
RoW
Tagrisso, Osimertinib
Seoul National University Hospital, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center
Locally Advanced or Metastatic NSCLC
09/25
12/25
NCT06205212: High-flow Nasal Oxygenation During Preoxygenation and Atelectasis

Recruiting
N/A
92
RoW
high-flow nasal oxygen, facemask
Seoul National University Hospital, SMG-SNU Boramae Medical Center
Anesthesia, General, Pulmonary Atelectasis
10/24
10/24
ICARUS, NCT05805280: IntravasCular Imaging-Guided Versus AngiogRaphy-GUided Drug-Eluting Stent Implantation for Fermoropopliteal Artery Disease

Recruiting
N/A
100
RoW
intravascular ultrasound-guided group, angiography-guided group
Asan Medical Center
Femoropopliteal Disease
12/25
12/25
DREAM-CCTA, NCT05801432: A Study to Evaluate Coronary Atherosclerosis in Patients With Diabetes Mellitus

Recruiting
N/A
511
RoW
Asan Medical Center
Diabetes Mellitus
12/25
12/25
NCT06216912: Gastric Volume in Paralyzed Obese Patients After High-flow Nasal Oxygen Therapy

Recruiting
N/A
60
RoW
Seoul National University Hospital, SMG-SNU Boramae Medical Center
Undefined
01/25
01/25
OBE-KMT22-01, NCT06250608: Evaluation of rSO2 Between Frontal Lesion Area and Normal Area of Brain by NIRSITX Using NIRS in Acute Ischemic Stroke Patients.

Recruiting
N/A
35
RoW
Pulse oximeter, NIRSITX
OBELAB, Inc., Helptrial Inc.
Acute Ischemic Stroke Patients
12/25
12/25
roboticPCI, NCT05981859: AVIAR(MX-02) Robotic-assisted Percutaneous Coronary Intervention

Completed
N/A
21
RoW
Asan Medical Center, LN Robotics
Percutaneous Coronary Intervention
03/24
04/24
NCT06441175: Effectiveness of Cricoid Pressure During Videolaryngoscopy Versus Direct Laryngoscopy

Not yet recruiting
N/A
140
NA
Intubation device order
Seoul National University Hospital, SMG-SNU Boramae Medical Center
Cricoid Pressure
07/25
07/26
NCT06076083: Multi-omics Database for Integrative Microbiome Analysis in a Cohort of Korean Patients With Ankylosing Spondylitis

Recruiting
N/A
600
RoW
Tae-Hwan Kim, Kyunghee University Medical Center
Ankylosing Spondylitis
12/25
12/27
NCT04259398: Anesthesia and Cancer Study: Colon Cancer

Active, not recruiting
N/A
797
RoW
Propofol, Sevoflurane
Seoul National University Hospital, Korean Society of Anesthesiologists, Bundang Seoul National University Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Seoul St. Mary's Hospital, Seoul National University Boramae Hospital
Cancer of Colon, Anesthesia
05/28
05/28
ASSIST, NCT05529459: Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD

Recruiting
N/A
2400
RoW
Percutaneous Coronary Intervention
Seung-Whan Lee, M.D., Ph.D., Biotronik Korea Co., Ltd
Coronary Disease
12/26
07/30
PROVE-DM, NCT05579626: Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus

Recruiting
N/A
4000
RoW
high-intensity statin arm, low-intensity statin plus ezetimibe
Seung-Whan Lee, M.D., Ph.D., Yuhan Corporation
Pre Diabetes, ASCVD
12/27
12/27
NCT04466189: Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy

Enrolling by invitation
N/A
120
RoW
National Cancer Center, Korea
Pancreas Cancer
08/28
08/28
PTA, NCT06022653: Asan Aorta and Peripheral Registry

Recruiting
N/A
6000
RoW
Treatment, Intervention
Asan Medical Center
Aorta Disease, Peripheral Artery Disease
12/34
12/44
NCT05467930: CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2

Recruiting
N/A
1000
US
Survey, Medical History Review, Sample Collection
Columbia University, Gilead Sciences
COVID-19, SARS CoV 2 Infection
05/26
05/27
NCT04466124: Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy

Enrolling by invitation
N/A
500
RoW
Liver Cancer Patients Treated With Proton Beam Therapy
National Cancer Center, Korea
Liver Cancer
08/28
08/28
NCT05213962: Local and Regional Radiotherapy for Nipple Sparing Mastectomy With Implant

Enrolling by invitation
N/A
128
RoW
National Cancer Center, Korea
Breast Cancer
12/28
12/28
Salamon, Agnes
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
08/24
09/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
COMMIT-CD, NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Not yet recruiting
3
290
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
05/28
05/28
COMMIT-UC, NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Not yet recruiting
3
350
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Ulcerative Colitis, Obesity or Overweight
04/28
04/28
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
2
212
Europe, US, RoW
Obefazimod, Placebo
Abivax S.A.
Moderately to Severely Active Crohn Disease
12/26
04/28
Stepek, David
VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Recruiting
4
304
Europe, Canada, US, RoW
Vedolizumab
Alimentiv Inc., Takeda
Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
01/27
09/28
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
08/24
09/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
140
Europe, Canada, Japan, US, RoW
Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
12/27
09/28
ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
2
212
Europe, US, RoW
Obefazimod, Placebo
Abivax S.A.
Moderately to Severely Active Crohn Disease
12/26
04/28
cekin, ayhan hilmi
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
COMMIT-CD, NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Not yet recruiting
3
290
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
05/28
05/28
COMMIT-UC, NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Not yet recruiting
3
350
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Ulcerative Colitis, Obesity or Overweight
04/28
04/28
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT06521879: Probiotic Use in Oral Iron Replacement Deficiency Anemia Patients Initiating Oral Iron Replacement

Completed
N/A
295
RoW
Lactobacillus plantarum 299v probiotic support
Antalya Training and Research Hospital
Iron Deficiency Anemia Treatment, Iron Deficiency Anemia
07/23
07/23
WANG, Yufang
NCT06609447: The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis

Recruiting
4
100
RoW
VSL#3, Placebo, Placebo (for VSL#3), Vedolizumab, Vedolizumab 300 mg Injection
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ulcerative Colitis
12/27
12/27
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Checkmark Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Checkmark Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Checkmark From LUCENT 1 trial for ulcerative colitis
More
Completed
3
1281
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis
01/21
05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Completed
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Recruiting
3
402
RoW
Vedolizumab IV, Placebo
Takeda
Moderately to Severely Active Ulcerative Colitis
05/28
07/28
TAPES, NCT06643689: Tranilast Vs. Steroids to Prevent Esophageal Stricture () After Endoscopic Resection for Superficial Neoplasms

Not yet recruiting
2
394
RoW
Tranilast, Dexamethasone
Second Affiliated Hospital, School of Medicine, Zhejiang University, The Third People's Hospital of Hangzhou, Xiangya Hospital of Central South University
Esophageal Stricture, Esophageal Neoplasms
12/27
12/28
Campos, Luciana Teixeira de
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
COMMIT-CD, NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Not yet recruiting
3
290
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
05/28
05/28
COMMIT-UC, NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Not yet recruiting
3
350
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Ulcerative Colitis, Obesity or Overweight
04/28
04/28
NCT05298657: The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment

Not yet recruiting
N/A
200
RoW
Fatima College of Health Sciences, ART Fertility Clinics LLC
Poor Response to Ovulation Induction, PCOS, Endometriosis, Infertility, Female
08/24
08/24
Vasconcellos, Eduardo Freire
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
ADVANCE, NCT06672549: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Recruiting
3
125
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight
02/27
03/27
NCT06672939: A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Recruiting
3
125
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight
02/27
03/27
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
ACHIEVE-5, NCT06109311: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Active, not recruiting
3
520
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
COMET-PACE, NCT05124210 / 2021-003717-18: Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

Terminated
2
8
US
Sotrovimab
GlaxoSmithKline, Vir Biotechnology, Inc.
COVID-19
06/23
06/23
PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended
2
279
Europe, US, RoW
zetomipzomib, KZR-616, placebo, matching placebo
Kezar Life Sciences, Inc.
Lupus Nephritis
05/26
07/26
NCT05669014: A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Active, not recruiting
2
12
Europe, US, RoW
Daxdilimab, HZN-7734, Placebo
Amgen
Idiopathic Inflammatory Myositis
03/25
10/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Tae Won
NEMO, NCT03128021: Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response

Completed
4
57
US
Escitalopram Pill, Lexapro, Placebo, Levomilnacipran Pill, Fetzima
Howard Aizenstein, Weill Cornell Institute of Geriatric Psychiatry, National Institute of Mental Health (NIMH)
Major Depressive Disorder
06/23
08/23
OPTIMIZE-APT, NCT05418556: Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent

Recruiting
4
3944
RoW
aspirin, clopidogrel, prasugrel, ticagrelor
Asan Medical Center
Coronary Artery Disease
08/27
12/28
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Recruiting
3
510
Europe, Canada, Japan, US, RoW
LY3650150, Placebo, Standard therapy for INCS
Eli Lilly and Company
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
10/26
02/27
NCT06545526: Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis

Recruiting
3
28
RoW
celecoxib monotherapy, celecoxib and metformin combination
Yonsei University
Familial Adenomatous Polyposis
06/26
06/26
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
NCT04296851: Niclosamide for Familial Adenomatous Polyposis

Recruiting
2
72
RoW
Niclosamide, placebo
Yonsei University
Familial Adenomatous Polyposis
12/22
02/23
NCT03435107: Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Completed
2
33
RoW
Durvalumab
Asan Medical Center
Metastatic Colorectal Cancer
04/23
04/23
DYNAMIC, NCT04954339: DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab

Active, not recruiting
2
40
RoW
Aatezolizumab plus Bevacizumab, Ticentriq plus Avastin
Tae Won Kim
Hepatocellular Carcinoma
06/26
12/26
SPECTRUM, NCT05253118: Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)

Active, not recruiting
2
28
RoW
Tislelizumab, BGB-A317, Pemetrexed
Seoul National University Hospital, Gyeongsang National University Hospital, Kyunghee University Medical Center, Inje University Haeundae Paik Hospital, Chungnam National University Hospital
DLBCL
12/25
02/26
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
140
Europe, Canada, Japan, US, RoW
Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
12/27
09/28
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
FORTE, NCT05503797 / 2022-000627-20: A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Recruiting
2
250
Europe, Canada, US, RoW
Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R)
Fore Biotherapeutics, Fore Biotherapeutics
Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors, Melanoma BRAF V600E/K Mutated, Thyroid Cancer
06/26
12/26
ACE, NCT05741060: Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers

Active, not recruiting
2
372
US
S-equol, Equelle, Placebo
Akira Sekikawa, National Institute on Aging (NIA)
Arterial Stiffness, White Matter Lesions, Cognitive Decline
10/26
01/27
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
NCT04696848: The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors

Terminated
1/2
25
RoW
CKD-516 plus Durvalumab, CKD-516 plus MEDI4736
Tae Won Kim
Colorectal Cancer, Solid Tumor
03/23
03/23
KEYNOTE-877, NCT03674567: Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

Completed
1/2
323
US, RoW
FLX475, pembrolizumab (KEYTRUDA®)
RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC
Advanced Cancer
12/24
12/24
NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Recruiting
1/2
110
US, RoW
EU101
Eutilex
Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer
09/25
12/25
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
NCT05394831: A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

Recruiting
1/2
150
US, RoW
JIN-A02
J Ints Bio
EGFR Mutant Advanced Non-small Cell Lung Cancer
09/26
09/26
DF1001-001, NCT04143711 / 2019-004706-10: Study of DF1001 in Patients with Advanced Solid Tumors

Recruiting
1/2
378
Europe, US, RoW
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics, Dragonfly Therapeutics, Inc.
Solid Tumor, Adult
10/26
12/26
IDE397-001, NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting
1
180
Europe, US, RoW
IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan
IDEAYA Biosciences
Solid Tumor
12/26
03/27
NCT03284502: HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
148
RoW
HM95573, cobimetinib, HM95573, cetuximab
Hanmi Pharmaceutical Company Limited
Locally Advanced Solid Tumor, Metastatic Solid Tumor
09/24
12/24
NCT05159440: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Active, not recruiting
1
70
US, RoW
TORL-2-307-MAB
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
12/24
12/25
NCT05156866: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Recruiting
1
70
US, RoW
TORL-2-307-ADC
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
02/26
02/27
ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting
1
198
Europe, US, RoW
ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1
Enliven Therapeutics
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
07/26
07/26
RELIF-C, NCT02865369: Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment

Not yet recruiting
N/A
103
RoW
Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks
Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb
Chronic Hepatitis C
12/18
12/22
NCT04656405: Efficacy of Online Real-time CPR Training

Recruiting
N/A
180
RoW
Online real-time quality measurement and feedback video-based CPR training, Online real-time feedback video-based CPR training without quality measurement, Conventional CPR training
Seoul National University Hospital
Cardiopulmonary Resuscitation, Education
12/21
03/22
NCT04239794: The Influence of Type of Anesthesia on Postoperative Pain

Active, not recruiting
N/A
468
RoW
Propofol, Propofol 2%, Sevoflurane, Sevoflurane inhalant product
Seoul National University Hospital
Colo-rectal Cancer, Anesthesia
12/23
01/24
NCT04203849: Prospective Cohort Study of Breast Cancer Patients Treated With Radiotherapy

Enrolling by invitation
N/A
5000
RoW
National Cancer Center, Korea
Breast Cancer
06/22
06/34
NCT05100485: Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108)

Completed
N/A
1000
RoW
Esophagogasrtoduodendoscopy, Hepatic venous pressure gradient
Hepatopancreatobiliary Surgery Institute of Gansu Province, Tianjin Second People's Hospital, The Third People's Hospital of Taiyuan, Ehime University Graduate School of Medicine, Korea University Ansan Hospital, Hyogo Medical University, Zagazing University Faculty of Medicine, Institute of Liver and Biliary Sciences (ILBS), Changi General Hospital, Ruijin Hospital
Compensated Advanced Chronic Liver Disease
01/23
01/23
NCT05559502: High Flow Nasal Oxygenation vs Endotracheal Intubation on Recovery Profiles in Laryngeal Microsurgery

Recruiting
N/A
52
RoW
HFNO group, Optiflow, ET group, Portex, Smiths Medical International Ltd., South East England, United Kingdom
Ajou University School of Medicine
Cough
06/24
06/24
NCT03969823: Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

Active, not recruiting
N/A
148
RoW
Tagrisso, Osimertinib
Seoul National University Hospital, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center
Locally Advanced or Metastatic NSCLC
09/25
12/25
NCT06205212: High-flow Nasal Oxygenation During Preoxygenation and Atelectasis

Recruiting
N/A
92
RoW
high-flow nasal oxygen, facemask
Seoul National University Hospital, SMG-SNU Boramae Medical Center
Anesthesia, General, Pulmonary Atelectasis
10/24
10/24
ICARUS, NCT05805280: IntravasCular Imaging-Guided Versus AngiogRaphy-GUided Drug-Eluting Stent Implantation for Fermoropopliteal Artery Disease

Recruiting
N/A
100
RoW
intravascular ultrasound-guided group, angiography-guided group
Asan Medical Center
Femoropopliteal Disease
12/25
12/25
DREAM-CCTA, NCT05801432: A Study to Evaluate Coronary Atherosclerosis in Patients With Diabetes Mellitus

Recruiting
N/A
511
RoW
Asan Medical Center
Diabetes Mellitus
12/25
12/25
NCT06216912: Gastric Volume in Paralyzed Obese Patients After High-flow Nasal Oxygen Therapy

Recruiting
N/A
60
RoW
Seoul National University Hospital, SMG-SNU Boramae Medical Center
Undefined
01/25
01/25
OBE-KMT22-01, NCT06250608: Evaluation of rSO2 Between Frontal Lesion Area and Normal Area of Brain by NIRSITX Using NIRS in Acute Ischemic Stroke Patients.

Recruiting
N/A
35
RoW
Pulse oximeter, NIRSITX
OBELAB, Inc., Helptrial Inc.
Acute Ischemic Stroke Patients
12/25
12/25
roboticPCI, NCT05981859: AVIAR(MX-02) Robotic-assisted Percutaneous Coronary Intervention

Completed
N/A
21
RoW
Asan Medical Center, LN Robotics
Percutaneous Coronary Intervention
03/24
04/24
NCT06441175: Effectiveness of Cricoid Pressure During Videolaryngoscopy Versus Direct Laryngoscopy

Not yet recruiting
N/A
140
NA
Intubation device order
Seoul National University Hospital, SMG-SNU Boramae Medical Center
Cricoid Pressure
07/25
07/26
NCT06076083: Multi-omics Database for Integrative Microbiome Analysis in a Cohort of Korean Patients With Ankylosing Spondylitis

Recruiting
N/A
600
RoW
Tae-Hwan Kim, Kyunghee University Medical Center
Ankylosing Spondylitis
12/25
12/27
NCT04259398: Anesthesia and Cancer Study: Colon Cancer

Active, not recruiting
N/A
797
RoW
Propofol, Sevoflurane
Seoul National University Hospital, Korean Society of Anesthesiologists, Bundang Seoul National University Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Seoul St. Mary's Hospital, Seoul National University Boramae Hospital
Cancer of Colon, Anesthesia
05/28
05/28
ASSIST, NCT05529459: Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD

Recruiting
N/A
2400
RoW
Percutaneous Coronary Intervention
Seung-Whan Lee, M.D., Ph.D., Biotronik Korea Co., Ltd
Coronary Disease
12/26
07/30
PROVE-DM, NCT05579626: Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus

Recruiting
N/A
4000
RoW
high-intensity statin arm, low-intensity statin plus ezetimibe
Seung-Whan Lee, M.D., Ph.D., Yuhan Corporation
Pre Diabetes, ASCVD
12/27
12/27
NCT04466189: Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy

Enrolling by invitation
N/A
120
RoW
National Cancer Center, Korea
Pancreas Cancer
08/28
08/28
PTA, NCT06022653: Asan Aorta and Peripheral Registry

Recruiting
N/A
6000
RoW
Treatment, Intervention
Asan Medical Center
Aorta Disease, Peripheral Artery Disease
12/34
12/44
NCT05467930: CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2

Recruiting
N/A
1000
US
Survey, Medical History Review, Sample Collection
Columbia University, Gilead Sciences
COVID-19, SARS CoV 2 Infection
05/26
05/27
NCT04466124: Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy

Enrolling by invitation
N/A
500
RoW
Liver Cancer Patients Treated With Proton Beam Therapy
National Cancer Center, Korea
Liver Cancer
08/28
08/28
NCT05213962: Local and Regional Radiotherapy for Nipple Sparing Mastectomy With Implant

Enrolling by invitation
N/A
128
RoW
National Cancer Center, Korea
Breast Cancer
12/28
12/28
Salamon, Agnes
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
08/24
09/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
COMMIT-CD, NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Not yet recruiting
3
290
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
05/28
05/28
COMMIT-UC, NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Not yet recruiting
3
350
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Ulcerative Colitis, Obesity or Overweight
04/28
04/28
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
2
212
Europe, US, RoW
Obefazimod, Placebo
Abivax S.A.
Moderately to Severely Active Crohn Disease
12/26
04/28
Stepek, David
VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Recruiting
4
304
Europe, Canada, US, RoW
Vedolizumab
Alimentiv Inc., Takeda
Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
01/27
09/28
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
08/24
09/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
140
Europe, Canada, Japan, US, RoW
Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
12/27
09/28
ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
2
212
Europe, US, RoW
Obefazimod, Placebo
Abivax S.A.
Moderately to Severely Active Crohn Disease
12/26
04/28
cekin, ayhan hilmi
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
COMMIT-CD, NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Not yet recruiting
3
290
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
05/28
05/28
COMMIT-UC, NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Not yet recruiting
3
350
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Ulcerative Colitis, Obesity or Overweight
04/28
04/28
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT06521879: Probiotic Use in Oral Iron Replacement Deficiency Anemia Patients Initiating Oral Iron Replacement

Completed
N/A
295
RoW
Lactobacillus plantarum 299v probiotic support
Antalya Training and Research Hospital
Iron Deficiency Anemia Treatment, Iron Deficiency Anemia
07/23
07/23
WANG, Yufang
NCT06609447: The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis

Recruiting
4
100
RoW
VSL#3, Placebo, Placebo (for VSL#3), Vedolizumab, Vedolizumab 300 mg Injection
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ulcerative Colitis
12/27
12/27
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Checkmark Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Checkmark Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Checkmark From LUCENT 1 trial for ulcerative colitis
More
Completed
3
1281
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis
01/21
05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Completed
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Recruiting
3
402
RoW
Vedolizumab IV, Placebo
Takeda
Moderately to Severely Active Ulcerative Colitis
05/28
07/28
TAPES, NCT06643689: Tranilast Vs. Steroids to Prevent Esophageal Stricture () After Endoscopic Resection for Superficial Neoplasms

Not yet recruiting
2
394
RoW
Tranilast, Dexamethasone
Second Affiliated Hospital, School of Medicine, Zhejiang University, The Third People's Hospital of Hangzhou, Xiangya Hospital of Central South University
Esophageal Stricture, Esophageal Neoplasms
12/27
12/28
Campos, Luciana Teixeira de
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
COMMIT-CD, NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Not yet recruiting
3
290
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
05/28
05/28
COMMIT-UC, NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Not yet recruiting
3
350
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Ulcerative Colitis, Obesity or Overweight
04/28
04/28
NCT05298657: The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment

Not yet recruiting
N/A
200
RoW
Fatima College of Health Sciences, ART Fertility Clinics LLC
Poor Response to Ovulation Induction, PCOS, Endometriosis, Infertility, Female
08/24
08/24
Vasconcellos, Eduardo Freire
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
ADVANCE, NCT06672549: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Recruiting
3
125
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight
02/27
03/27
NCT06672939: A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Recruiting
3
125
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight
02/27
03/27
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
ACHIEVE-5, NCT06109311: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Active, not recruiting
3
520
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
COMET-PACE, NCT05124210 / 2021-003717-18: Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

Terminated
2
8
US
Sotrovimab
GlaxoSmithKline, Vir Biotechnology, Inc.
COVID-19
06/23
06/23
PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended
2
279
Europe, US, RoW
zetomipzomib, KZR-616, placebo, matching placebo
Kezar Life Sciences, Inc.
Lupus Nephritis
05/26
07/26
NCT05669014: A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Active, not recruiting
2
12
Europe, US, RoW
Daxdilimab, HZN-7734, Placebo
Amgen
Idiopathic Inflammatory Myositis
03/25
10/25

Download Options